CHANDAN HEALTHCARE LTD Stock Price Today (NSE: CHANDAN)
Fundamental Score
CHANDAN HEALTHCARE LTD Share Price — Live NSE/BSE Price, Fundamentals & Analysis
CHANDAN HEALTHCARE LTD share price today is ₹250.60, up +8.44% on NSE/BSE as of 16 April 2026. CHANDAN HEALTHCARE LTD (CHANDAN) is a Small-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹826.72 (Cr). The 52-week high for CHANDAN share price is ₹358.00 and the 52-week low is ₹230.00. At a P/E ratio of 30.47x, CHANDAN is currently trading below its industry average P/E of 39.28x. The company has a Return on Equity (ROE) of 27.08% and a debt-to-equity ratio of 0.48.
CHANDAN HEALTHCARE LTD Share Price Chart — NSE/BSE Historical Performance
AI Research Briefing
Powered by Gemini · 2026-04-15
Regional diagnostics play expanding aggressively, but liquidity and execution risks loom large.
⚡ WHAT'S HAPPENING NOW (last 2-4 weeks): Chandan Healthcare acquired Nishkam Imaging in New Delhi. Also, Chandan secured a tender for a 1.5 Tesla MRI system at Civil Hospital Rohtak. 🧠 CORE STORY (THE REAL GAME): Chandan is a play on the expansion of diagnostic services in Tier 2/3 cities, leveraging government contracts and partnerships for growth. It's about capturing market share in underserved areas through affordable and accessible healthcare. 🔥 WHAT IS DRIVING THE STOCK: 1. **Government PPP Projects:** Chandan secured a ₹26 Cr government PPP project. 2. **Expansion:** Chandan is expanding across Uttar Pradesh, Uttarakhand, Rajasthan, Bihar, Madhya Pradesh, and Delhi, with plans for Chhattisgarh and Western Uttar Pradesh. They've started six comprehensive diagnostic centers and plan to open one in Raipur next month. ⚖️ BULL vs BEAR: Bull: Expansion into Tier 2/3 cities with government support drives revenue growth. Focus on cost-efficiency using refurbished equipment maintains profitability. Bear: Small-cap with inherent liquidity risk. Expansion costs are currently impacting EBITDA margins. Dependence on government contracts exposes them to payment delays and policy changes. Revenue concentration in North India creates geographic risk. 💣 WHAT MARKET IS PRICING: The market is pricing in continued rapid expansion and margin improvement. If expansion slows or margins compress, expect a correction. 🎯 BOTTOM LINE: Chandan Healthcare is a regional diagnostics player undergoing aggressive expansion, but liquidity risk and execution challenges remain significant concerns.
- Acquisition of Nishkam Imaging
- Secured MRI tender at Civil Hospital Rohtak
- Expansion into multiple states
- Significant order wins in PPP projects
- Successful integration of acquired entities
- Faster-than-expected margin improvement
- Micro-cap liquidity risk
- Geographic revenue concentration
- High expansion costs impacting EBITDA
FII decreased their holding by 2.75% and DII decreased their holding by 1.3% [cite: brief].
Increasing healthcare spending and government support for healthcare infrastructure are tailwinds.
Chandan secured a ₹26 Cr government PPP project.
Free Cash Flow 5Y: ₹None Cr [cite: brief].
Expect continued expansion and revenue growth, but monitor margin compression and execution risks. Focus on government contracts and partnership performance over the next 6 months.
Primary Thesis Risk
Failure to execute expansion plans and maintain profitability will crush the thesis.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
CHANDAN HEALTHCARE LTD Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
CHANDAN HEALTHCARE Share Price Analysis: A ROCE-Focused Perspective
The healthcare service provider industry is witnessing a surge in demand, driven by an aging population and increasing awareness regarding preventative care. This analysis focuses on CHANDAN HEALTHCARE share price, currently trading at ₹271.85, from a Return on Capital Employed (ROCE) perspective. The company's Price-to-Earnings (PE) ratio stands at 30.47, while its ROCE is reported at 28.85%. This analysis is part of a more extensive, 80-parameter fundamental audit of the company, verified by Sweta Mishra.
CHANDAN HEALTHCARE's ROCE of 28.85% warrants deeper investigation. ROCE measures how efficiently a company generates profits from its capital employed. A higher ROCE suggests superior capital allocation and operational efficiency. This robust ROCE potentially contributes significantly to the company's economic moat, providing a competitive advantage by demonstrating its ability to generate greater returns compared to competitors. This sustained efficiency can allow the company to reinvest in growth opportunities, further strengthening its market position. Investors often view high ROCE companies as less risky and capable of delivering sustainable long-term value.
Comparing CHANDAN HEALTHCARE with its peers provides valuable context. For example,
Suraksha Diagnostic Ltd management quality and strategic decisions significantly influence their operational performance and ROCE. While data for a direct ROCE comparison is needed, analyzing management commentaries and historical performance suggests differing approaches to capital allocation and operational efficiency between CHANDAN HEALTHCARE and Suraksha Diagnostic Ltd. A detailed comparative analysis of their financial statements, specifically focusing on capital expenditure and working capital management, could reveal key insights into the drivers behind their respective ROCE figures.In conclusion, CHANDAN HEALTHCARE's reported 28.85% ROCE is a significant factor to consider when evaluating the company's financial health. Further investigation into the sustainability of this ROCE, coupled with a peer analysis that includes Aspira Pathlab & Diagnostics Limited and Gian Life Care Ltd, is crucial to understanding the potential future trajectory of the company and its share price. This analysis is purely observational and does not constitute investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
CHANDAN HEALTHCARE LTD Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CHANDAN across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Return on Equity (27.08%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (28.85%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 30.47 vs Industry: 39.28)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (46.62%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (22.94%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Interest Coverage (8.51x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Limited Institutional Interest (FII+DII: 6.13%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
CHANDAN HEALTHCARE LTD Financial Statements
Comprehensive financial data for CHANDAN HEALTHCARE LTD including income statement, balance sheet and cash flow
About CHANDAN (CHANDAN HEALTHCARE LTD)
CHANDAN HEALTHCARE LTD (CHANDAN) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Healthcare Service Provider se...ctor with a current market capitalisation of ₹826.72 (Cr). CHANDAN HEALTHCARE LTD has delivered a Return on Equity (ROE) of 27.08% and a ROCE of 28.85%. The debt-to-equity ratio stands at 0.48, reflecting the company's capital structure. Investors tracking CHANDAN share price can monitor key metrics including P/E ratio, promoter holding of 49.47%, and quarterly earnings growth.
Company Details
CHANDAN Share Price: Frequently Asked Questions
What is the current share price of CHANDAN HEALTHCARE LTD (CHANDAN)?
As of 16 Apr 2026, 11:00 am IST, CHANDAN HEALTHCARE LTD share price is ₹250.60. The CHANDAN stock has a market capitalisation of ₹826.72 (Cr) on NSE/BSE.
Is CHANDAN share price Overvalued or Undervalued?
CHANDAN share price is currently trading at a P/E ratio of 30.47x, compared to the industry average of 39.28x. Based on this relative valuation, the CHANDAN HEALTHCARE LTD stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of CHANDAN share price?
The 52-week high of CHANDAN share price is ₹358.00 and the 52-week low is ₹230.00. These values are updated daily from NSE/BSE price data.
What factors affect the CHANDAN HEALTHCARE LTD share price?
Key factors influencing CHANDAN share price include quarterly earnings growth (Sales Growth: 22.94%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is CHANDAN HEALTHCARE LTD a good stock for long-term investment?
CHANDAN HEALTHCARE LTD shows a 5-year Profit Growth of N/A% and an ROE of 27.08%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.48 before investing in CHANDAN shares.
How does CHANDAN HEALTHCARE LTD compare with its industry peers?
CHANDAN HEALTHCARE LTD competes with major peers in the Healthcare Service Provider. Investors should compare CHANDAN share price P/E of 30.47x and ROE of 27.08% against the industry averages to determine competitive standing.
What is the P/E ratio of CHANDAN and what does it mean?
CHANDAN share price has a P/E ratio of 30.47x compared to the industry average of 39.28x. Investors pay ₹30 for every ₹1 of annual earnings.
How is CHANDAN performing according to Bull Run's analysis?
CHANDAN has a Bull Run fundamental score of 46.5/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does CHANDAN belong to?
CHANDAN operates in the Healthcare Service Provider industry. This classification helps understand the competitive landscape and sector-specific trends affecting CHANDAN HEALTHCARE LTD share price.
What is Return on Equity (ROE) and why is it important for CHANDAN?
CHANDAN has an ROE of 27.08%, which indicates excellent management efficiency. ROE measures how efficiently CHANDAN HEALTHCARE LTD generates profits from shareholders capital.
How is CHANDAN debt-to-equity ratio and what does it indicate?
CHANDAN has a debt-to-equity ratio of 0.48, which indicates moderate leverage that should be monitored.
What is CHANDAN dividend yield and is it a good dividend stock?
CHANDAN offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in CHANDAN HEALTHCARE LTD shares.
How has CHANDAN share price grown over the past 5 years?
CHANDAN has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in CHANDAN and why does it matter?
Promoters hold 49.47% of CHANDAN shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in CHANDAN HEALTHCARE LTD.
What is CHANDAN market capitalisation category?
CHANDAN has a market capitalisation of ₹827 crores, placing it in the Small-cap category.
How volatile is CHANDAN stock?
CHANDAN has a beta of N/A. A beta > 1 suggests the CHANDAN HEALTHCARE LTD stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is CHANDAN operating profit margin trend?
CHANDAN has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is CHANDAN quarterly performance?
Recent quarterly performance shows CHANDAN HEALTHCARE LTD YoY Sales Growth of 22.94% and YoY Profit Growth of 46.62%.
What is the institutional holding pattern in CHANDAN?
CHANDAN has FII holding of 1.11% and DII holding of 5.02%. Significant institutional holding often suggests professional confidence in the CHANDAN HEALTHCARE LTD stock.